What is a Phase 3 Clinical Trial for a Vaccine Candidate?
Through the ACTIV program, NIH is working with many partners to develop safe and effective vaccines for COVID-19. Learn how candidate vaccines are tested through the different phases of clinical trials.
Learn about monoclonal antibodies, which are being tested in NIH clinical trials as a potential treatment for COVID-19. Learn more about these trials
NIH and Moderna launched a Phase 3 clinical trial in July 2020 to study COVID-19 vaccine candidate mRNA-1273. Learn more
In August 2020 NIH announced ACTIV-2, a Phase 2/3 clinical trial to study the use of monoclonal antibodies as a treatment for COVID-19 in an outpatient setting for people with mild to moderate COVID-19.
In August 2020 NIH announced a Phase 3 clinical trial to study the use of monoclonal antibodies as a treatment for hospitalized COVID-19 patients as part of ACTIV-3. Learn more
From left to right: Dr. Anthony Fauci, director of NIH’s National Institute of Allergy and Infectious Diseases, Dr. Matt Hepburn, Vaccine Lead for Operation Warp Speed, and NIH Director Dr. Francis Collins at NIH Building 1 on July 27, 2020, after a press briefing on the Phase 3 trial launch of the investigational vaccine mRNA-1273 for COVID-19. (NIH News Release) Photo credit: NIH